Enterprise Value
1.732B
Cash
870.1M
Avg Qtr Burn
-22.05M
Short % of Float
7.17%
Insider Ownership
9.27%
Institutional Own.
85.72%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Optune Gio® w/ radiation therapy & temozolomide (TMZ) Details Glioblastoma, Cancer | Phase 3 Data readout | |
Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer | Phase 3 Data readout | |
Stereotactic radiosurgery (SRS) w/ NovoTTF-200M Details Brain metastases | Phase 3 Update | |
Immune checkpoint inhibitors or docetaxel w/ NovoTTF-200T Details Non-small cell lung carcinoma | Phase 3 Update | |
Paclitaxel w/ NovoTTF-100L(O) Details Ovarian cancer | Phase 3 Update |